Targeting fatty acid biosynthesis is a well-established antibacterial strategy: for example, the frontline tuberculosis drug isoniazid exerts its bactericidal activity by inhibiting the enoyl-ACP reductase InhA, a homologue of FabI, thereby blocking mycolic acid and fatty acid synthesis [93]. Here, INHA is linked to tuberculosis.